TY - JOUR
T1 - Extracellular vesicles as cancer liquid biopsies
T2 - From discovery, validation, to clinical application
AU - Zhao, Zhen
AU - Fan, Jia
AU - Hsu, Yen Michael S.
AU - Lyon, Christopher J.
AU - Ning, Bo
AU - Hu, Ye
N1 - Funding Information:
The work was primarily supported by research funding provided by NIH (U01CA214254, R01HD090927, R01AI122932, R01AI113725 and R21Al126361), Arizona Biomedical Research Commission (ABRC) young investigator award and ASU-Mayo seed funds.
Publisher Copyright:
© 2019 The Royal Society of Chemistry.
PY - 2019/4/7
Y1 - 2019/4/7
N2 - Substantial research has been devoted to elucidate the roles that extracellular vesicles (EVs) play in the regulation of both normal and pathological processes, and multiple studies have demonstrated their potential as a source of cancer biomarkers. However, several factors have slowed the development of liquid biopsy EV biomarkers for cancer diagnosis, including logistical and technical difficulties associated with reproducibly obtaining highly purified EVs suitable for diagnostic analysis. Significant effort has focused on addressing these problems, and multiple groups have now reported EV analysis methods using liquid biopsies that have the potential for clinical translation. However, there are still important issues that must be addressed if these discoveries and technical advances are to be used for clinical translation of EV cancer biomarkers from liquid biopsies. To address these issues, this review focuses on the potential application of EV biomarkers for diagnosis of major cancer types, discussing approaches for EV biomarker discovery and verification, EV clinical assay development, analytical and clinical validation, clinical trials, regulatory submission, and end user utilization for the intended clinical application. This review also discusses key difficulties related to these steps, and recommendations for how to best accomplish steps in order to translate EV-based biomarkers into clinical settings.
AB - Substantial research has been devoted to elucidate the roles that extracellular vesicles (EVs) play in the regulation of both normal and pathological processes, and multiple studies have demonstrated their potential as a source of cancer biomarkers. However, several factors have slowed the development of liquid biopsy EV biomarkers for cancer diagnosis, including logistical and technical difficulties associated with reproducibly obtaining highly purified EVs suitable for diagnostic analysis. Significant effort has focused on addressing these problems, and multiple groups have now reported EV analysis methods using liquid biopsies that have the potential for clinical translation. However, there are still important issues that must be addressed if these discoveries and technical advances are to be used for clinical translation of EV cancer biomarkers from liquid biopsies. To address these issues, this review focuses on the potential application of EV biomarkers for diagnosis of major cancer types, discussing approaches for EV biomarker discovery and verification, EV clinical assay development, analytical and clinical validation, clinical trials, regulatory submission, and end user utilization for the intended clinical application. This review also discusses key difficulties related to these steps, and recommendations for how to best accomplish steps in order to translate EV-based biomarkers into clinical settings.
UR - http://www.scopus.com/inward/record.url?scp=85063487614&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063487614&partnerID=8YFLogxK
U2 - 10.1039/c8lc01123k
DO - 10.1039/c8lc01123k
M3 - Review article
C2 - 30882822
AN - SCOPUS:85063487614
SN - 1473-0197
VL - 19
SP - 1114
EP - 1140
JO - Lab on a Chip
JF - Lab on a Chip
IS - 7
ER -